The British journal of dermatology
-
Randomized Controlled Trial Multicenter Study
Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P).
Ixekizumab is an interleukin-17A antagonist approved for treatment of moderate-to-severe plaque psoriasis with a recommended 160-mg starting dose, then 80 mg every 2 weeks (Q2W) to week 12, and every 4 weeks (Q4W) thereafter. ⋯ Ixekizumab Q2W had higher efficacy at week 52 than ixekizumab Q4W, with no increase in safety events.